The table lists genes associated with familial cancer risk for which there is consensus by the majority of Australian family cancer and genetics servicesr that pathogenic variants are clinically actionable for diagnostic and/or predictive gene testing. This list has been reviewed, refined and approved by the eviQ Cancer Genetics Reference Committees.
Clinical genetics services or familial cancer centres will assess the clinical utility of offering gene testing to individual patients referred to them. See eviQ's Guide for health professionals ordering genetic testing for information about ordering genetic testing.
When considering testing of genes as part of a panel, it is recommended that included genes be relevant to the patient’s clinical picture (phenotype).
There are many other genes associated with cancer risks for which testing may be considered appropriate in the setting of a rare phenotype.
Predictive testing should not be offered when a variant of uncertain significance or benign/likely benign variant has been identified in a family
The information contained in this document is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to care or treatment. Any clinician seeking to apply or consult this document is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information sources. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au
- First approved:
- Last reviewed:
- Review due:
The currency of this information is guaranteed only up until the date of printing, for any updates please check:
09 Dec 2022